{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,18]],"date-time":"2026-04-18T17:23:34Z","timestamp":1776533014170,"version":"3.51.2"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,2,18]],"date-time":"2021-02-18T00:00:00Z","timestamp":1613606400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,2,18]],"date-time":"2021-02-18T00:00:00Z","timestamp":1613606400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Med Case Reports"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Myelomeningocele, which causes a neurogenic bladder, is usually treated with anticholinergics in children with neurogenic detrusor overactivity (NDO); however, anticholinergics cause side effects such as dry mouth, constipation, attention deficit, and inadequate reduction in detrusor leak point pressure. Vibegron, a novel selective beta-3 adrenoreceptor agonist, is a well-established alternative to anticholinergics in adults with an overactive bladder. It remains unknown whether this agent can be used for pediatric patients. We report the case of a girl with anticholinergic-resistant NDO due to tethered cord syndrome after myelomeningocele repair, who was treated with vibegron.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Case presentation<\/jats:title>\n                <jats:p>A 4-year-old Filipino girl had increased frequency of daytime urinary incontinence and foul-smelling urine since the age of 3. Clinical examination revealed constipation, and urinalysis revealed bacteriuria. Voiding cystourethrography revealed an enlarged and trabeculated bladder without vesicoureteral reflux. On the urodynamic study (UDS), she was found to have detrusor overactivity (DO) and low bladder compliance. She could not void and was diagnosed with overflow incontinence. Clean intermittent catheterization (CIC) and orally administered propiverine (0.8\u00a0mg\/kg\/day) were initiated, and urinary incontinence was resolved. She underwent a UDS annually; the UDS at 6 years of age still revealed DO and low bladder compliance in spite of receiving propiverine. The treatment was switched from propiverine to vibegron (1.4 mg\/kg\/day). On the UDS after a 5-week treatment schedule of vibegron, the DO disappeared and the bladder compliance improved. CIC and orally administered vibegron have been continued for 7 months so far, and she has had no urinary tract infection with no drug-related adverse events.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p> Vibegron was effective and well tolerated in the treatment of a pediatric patient with NDO. Vibegron improved the urodynamic parameters for anticholinergic-resistant neurogenic bladder. This agent can be a beneficial and preferable alternative therapeutic agent to anticholinergics in patients with anticholinergic-resistant NDO.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13256-020-02564-w","type":"journal-article","created":{"date-parts":[[2021,2,20]],"date-time":"2021-02-20T11:40:36Z","timestamp":1613821236000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Urodynamic effectiveness of a beta-3 adrenoreceptor agonist (vibegron) for a pediatric patient with anticholinergic-resistant neurogenic detrusor overactivity: a case report"],"prefix":"10.1186","volume":"15","author":[{"given":"Taiki","family":"Kato","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9624-2009","authenticated-orcid":false,"given":"Kentaro","family":"Mizuno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hidenori","family":"Nishio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahiro","family":"Yasui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yutaro","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,2,18]]},"reference":[{"issue":"Suppl 1","key":"2564_CR1","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1046\/j.1464-410X.92.s1.2.x","volume":"92","author":"SB Bauer","year":"2003","unstructured":"Bauer SB. The management of the myelodysplastic child: a paradigm shift. BJU Int. 2003;92(Suppl 1):23\u20138.","journal-title":"BJU Int."},{"key":"2564_CR2","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1046\/j.1464-410x.2001.02152.x","volume":"87","author":"P Ferrara","year":"2001","unstructured":"Ferrara P, D\u2019Aleo CM, Tarquini E, Salvatore S, Salvaggio E. Side-effects of oral or intravesical oxybutynin chloride in children with spina bifida. BJU Int. 2001;87:674\u20138.","journal-title":"BJU Int."},{"key":"2564_CR3","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1016\/j.jpurol.2011.07.014","volume":"8","author":"H Schulte-Baukloh","year":"2012","unstructured":"Schulte-Baukloh H, Murtz G, Heine G, Austin P, Miller K, Michael T, et al. Urodynamic effects of propiverine in children and adolescents with neurogenic bladder: results of a prospective long-term study. J Pediatr Urol. 2012;8:386\u201392.","journal-title":"J Pediatr Urol."},{"key":"2564_CR4","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1016\/j.eururo.2017.12.022","volume":"73","author":"M Yoshida","year":"2018","unstructured":"Yoshida M, Takeda M, Gotoh M, Nagai S, Kurose T. Vibegron, a novel potent and selective \u03b2(3)-adrenoreceptor agonist, for the treatment of patients with overactive bladder: a randomized, double-blind, placebo-controlled phase 3 study. Eur Urol. 2018;73:783\u201390.","journal-title":"Eur Urol."},{"key":"2564_CR5","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1111\/iju.13596","volume":"25","author":"M Yoshida","year":"2018","unstructured":"Yoshida M, Kakizaki H, Takahashi S, Nagai S, Kurose T. Long-term safety and efficacy of the novel beta3-adrenoreceptor agonist vibegron in Japanese patients with overactive bladder: a Phase III prospective study. Int J Urol. 2018;25:668\u201375.","journal-title":"Int J Urol."},{"issue":"101","key":"2564_CR6","first-page":"e1","volume":"12","author":"A Alzahrani","year":"2016","unstructured":"Alzahrani A, Alsowayan O, Farmer JP, Capolicchio JP, Jednak R, El-Sherbiny M. Comprehensive analysis of the clinical and urodynamic outcomes of secondary tethered spinal cord before and after spinal cord untethering. J Pediatr Urol. 2016;12(101):e1-6.","journal-title":"J Pediatr Urol."},{"key":"2564_CR7","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.urology.2014.10.008","volume":"85","author":"S Yener","year":"2015","unstructured":"Yener S, Thomas DT, Hicdonmez T, Dagcinar A, Bayri Y, Kaynak A, et al. The effect of untethering on urologic symptoms and urodynamic parameters in children with primary tethered cord syndrome. Urology. 2015;85:221\u20136.","journal-title":"Urology."},{"key":"2564_CR8","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1007\/s00381-016-3053-y","volume":"32","author":"M Geyik","year":"2016","unstructured":"Geyik M, Geyik S, \u015een H, Pusat S, Alptekin M, Y\u0131lmaz AE, et al. Urodynamic outcomes of detethering in children: experience with 46 pediatric patients. Childs Nerv Syst. 2016;32:1079\u201384.","journal-title":"Childs Nerv Syst."},{"key":"2564_CR9","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1007\/s00345-018-2576-0","volume":"37","author":"JS Park","year":"2019","unstructured":"Park JS, Lee YS, Lee CN, Kim SH, Kim SW, Han SW. Efficacy and safety of mirabegron, a \u03b23-adrenoceptor agonist, for treating neurogenic bladder in pediatric patients with spina bifida: a retrospective pilot study. World J Urol. 2019;37:1665\u201370.","journal-title":"World J Urol"},{"key":"2564_CR10","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1111\/luts.12053","volume":"7","author":"O Yamaguchi","year":"2015","unstructured":"Yamaguchi O, Marui E, Igawa Y, Takeda M, Nishizawa O, Ikeda Y, et al. Efficacy and safety of the selective \u03b23-adrenoceptor agonist mirabegron in Japanese patients with overactive bladder: a randomized, double-blind, placebo-controlled, dose-finding study. Lower Urinary Tract Symptoms. 2015;7:84\u201392.","journal-title":"Lower Urinary Tract Symptoms."},{"key":"2564_CR11","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/j.eururo.2018.03.020","volume":"74","author":"C Kelleher","year":"2018","unstructured":"Kelleher C, Hakimi Z, Zur R, Siddiqui E, Maman K, Aballea S, et al. Efficacy and tolerability of mirabegron compared with antimuscarinic monotherapy or combination therapies for overactive bladder: a systematic review and network meta-analysis. Eur Urol. 2018;74:324\u201333.","journal-title":"Eur Urol."},{"key":"2564_CR12","doi-asserted-by":"publisher","DOI":"10.1007\/s00345-019-03040-x","author":"E El Helou","year":"2019","unstructured":"El Helou E, Labaki C, Chebel R, El Helou J, Abi Tayeh G, Jalkh G, et al. The use of mirabegron in neurogenic bladder: a systematic review. World J Urol. 2019. https:\/\/doi.org\/10.1007\/s00345-019-03040-x.","journal-title":"World J Urol."},{"key":"2564_CR13","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1111\/iju.12867","volume":"22","author":"J Kamei","year":"2015","unstructured":"Kamei J, Furuta A, Akiyama Y, Niimi A, Ichihara K, Fujimura T, et al. Video-urodynamic effects of mirabegron, a \u03b23-adrenoceptor agonist, in patients with low-compliance bladder. Int J Urol. 2015;22:956\u201361.","journal-title":"Int J Urol."},{"key":"2564_CR14","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1111\/iju.14264","volume":"27","author":"S Fujinaga","year":"2020","unstructured":"Fujinaga S, Watanabe Y, Nakagawa M. Efficacy of the novel selective beta3-adrenoreceptor agonist vibegron for treatment-resistant monosymptomatic nocturnal enuresis in children. Int J Urol. 2020;27:693\u20134.","journal-title":"Int J Urol."},{"key":"2564_CR15","first-page":"322","volume":"14","author":"T Sundin","year":"1977","unstructured":"Sundin T, Dahlstr\u00f6m A, Norl\u00e9n L, Svedmyr N. The sympathetic innervation and adrenoreceptor function of the human lower urinary tract in the normal state and after parasympathetic denervation. Invest Urol. 1977;14:322\u20138.","journal-title":"Invest Urol"}],"container-title":["Journal of Medical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-020-02564-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13256-020-02564-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-020-02564-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,20]],"date-time":"2021-02-20T12:06:05Z","timestamp":1613822765000},"score":1,"resource":{"primary":{"URL":"https:\/\/jmedicalcasereports.biomedcentral.com\/articles\/10.1186\/s13256-020-02564-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,18]]},"references-count":15,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["2564"],"URL":"https:\/\/doi.org\/10.1186\/s13256-020-02564-w","relation":{},"ISSN":["1752-1947"],"issn-type":[{"value":"1752-1947","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,18]]},"assertion":[{"value":"29 July 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 October 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 February 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was conducted in accordance with the fundamental principles of the Declaration of Helsinki.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patient\u2019s mother for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"86"}}